Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · IEX Real-Time Price · USD
3.530
-0.110 (-3.02%)
At close: Jul 19, 2024, 4:00 PM
3.670
+0.140 (3.97%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.
The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
The company is headquartered in Boston, Massachusetts.
Akari Therapeutics, Plc
| Country | United Kingdom |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Samir Rashmikant Patel M.D. |
Contact Details
Address: 22 Boston Wharf Road, Fl 7 Boston, Massachusetts 02210 United States | |
| Phone | (646) 350-0702 |
| Website | akaritx.com |
Stock Details
| Ticker Symbol | AKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001541157 |
| CUSIP Number | 00972G108 |
| ISIN Number | US00972G2075 |
| Employer ID | 98-1034922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Rachelle Suzanne Jacques | President, Chief Executive Officer and Director |
| Wendy F. DiCicco CPA | Interim Chief Financial Officer |
| Melissa Bradford-Klug | Chief Operating Officer |
| Dr. Miles Nunn | Chief Scientific Officer |
| Dr. John F. Neylan III, M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jun 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 18, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 7, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jun 5, 2024 | 8-K | Current Report |
| Jun 4, 2024 | 425 | Filing |
| Jun 4, 2024 | 8-K | Current Report |
| Jun 4, 2024 | ARS | Filing |
| Jun 3, 2024 | DEF 14A | Other definitive proxy statements |
| May 16, 2024 | 8-K | Current Report |